Published in Cardiovasc Diabetol on January 08, 2015
Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Mol Med (2015) 0.77
Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update. J Cardiovasc Pharmacol (2015) 0.77
Advanced Glycation End Products Impair Voltage-Gated K+ Channels-Mediated Coronary Vasodilation in Diabetic Rats. PLoS One (2015) 0.75
Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol (2017) 0.75
DNA-aptamers raised against AGEs as a blocker of various aging-related disorders. Glycoconj J (2016) 0.75
Connexin 43 is required for the maintenance of mitochondrial integrity in brown adipose tissue. Sci Rep (2017) 0.75
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 12.33
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01
Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 8.92
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med (1988) 7.22
ICAM-1 signaling in endothelial cells. Pharmacol Rep (2009) 3.06
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest (2003) 2.95
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest (2001) 2.07
Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des (2005) 2.06
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med (2000) 1.42
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J (2002) 1.32
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol (2013) 1.31
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem (2006) 1.30
The role of AGEs in cardiovascular disease. Curr Pharm Des (2008) 1.29
Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia (1998) 1.26
AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging (2010) 1.21
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun (2009) 1.19
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res (2011) 1.10
Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway. Cardiovasc Diabetol (2014) 1.09
Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes (1996) 1.09
Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther (2010) 1.04
Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res (2011) 0.99
Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res (2006) 0.98
Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res (2007) 0.97
Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett (2002) 0.96
Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract (2007) 0.95
Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys (2007) 0.94
Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care (2012) 0.91
Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol (2013) 0.91
Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care (2014) 0.90
Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des (2008) 0.90
DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes (2013) 0.89
Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther (2011) 0.89
Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res (2007) 0.87
Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med (2006) 0.87
A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost (2011) 0.86
In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes. Microvasc Res (2007) 0.86
Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol (2014) 0.85
Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-β1 RAGE. J Diabetes (2014) 0.85
Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res (2007) 0.82
DNA aptamer raised against advanced glycation end products (AGEs) improves glycemic control and decreases adipocyte size in fructose-fed rats by suppressing AGE-RAGE axis. Horm Metab Res (2014) 0.81
Pigment epithelium-derived factor (PEDF) binds to caveolin-1 and inhibits the pro-inflammatory effects of caveolin-1 in endothelial cells. Biochem Biophys Res Commun (2013) 0.81
The modelling of blood coagulation using the quartz crystal microbalance. J Biomech (2012) 0.79
Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells. Microvasc Res (2013) 0.79
Detection and determination of glyceraldehyde-derived pyridinium-type advanced glycation end product in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem (2007) 0.78
DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab Invest (2014) 0.77
DNA aptamer raised against advanced glycation end products inhibits neointimal hyperplasia in balloon-injured rat carotid arteries. Int J Cardiol (2014) 0.77
Pigment epithelium-derived factor (PEDF) blocks high glucose-induced inflammatory reactions in endothelial cells through its anti-oxidative properties. Int J Cardiol (2013) 0.77
Isolation and identification of the 3-hydroxy-5-hydroxymethyl-pyridinium compound as a novel advanced glycation end product on glyceraldehyde-related Maillard reaction. Biosci Biotechnol Biochem (2003) 0.76